Loading stock data…
ANIP
$78.71-3.15 (-3.85%)
After Hours$78.40-0.31 (-0.39%)· Last close May 11
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANI Pharmaceuticals, Inc. in the Healthcare sector is trading at $78.71. The stock is currently 21% below its 52-week high of $99.50, remaining 5.4% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ANIP maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$78.71
Potential Downside
13.4%
Whystock Fair Value$68.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$109.88+39.6%
Range$90.00 – $124.00
Fundamentals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.49%
Volume
Today's trading volume
895,733
Recent News
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
Zacks.com featured highlights include ANI, Cummins and Seadrill
ANI, Cummins and Seadrill have been highlighted in this Screen of The Week article.
Is ANI Pharmaceuticals (ANIP) Still Attractively Priced After Recent Pipeline Developments?
If you are wondering whether ANI Pharmaceuticals at around US$83.91 is still reasonably priced or already stretched, the starting point is to understand how the current market price lines up against different measures of value. The stock has returned 5.6% over the last week, 5.6% over the past month, 7.0% year to date and 17.3% over the last year, so recent price action is important context for any assessment of upside or downside. Recent company updates around its product portfolio and...
ANI Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
ANI Pharmaceuticals Inc (ANIP) reports a robust 20% revenue increase and raises 2026 guidance, driven by rare disease and generics success.